Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Surveys and Questionnaires 16Bevacizumab 14Cisplatin 12Blood Specimen Collection 11Drug Therapy 10Standard of Care 9Nivolumab 9Gemcitabine 9Cetuximab 7pembrolizumab 6Specimen Handling 6S 1 (combination) 6Endoscopic Mucosal Resection 6Cyclophosphamide 6atezolizumab 5Sunitinib 5Radiotherapy 5Folfox protocol 5Educational Status 5Docetaxel 5fludarabine 4aldesleukin 4Radiosurgery 4Pemetrexed 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Nadroparin × Gastrointestinal × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡